The Brave New World of Genetic Testing in the Management of the Dyslipidaemias
Affiliations
- PMID: 32097179
- DOI: 10.1097/HCO.0000000000000721
Abstract
Purpose of review: With the exception of familial hypercholesterolaemia, the value of genetic testing for managing dyslipidaemias is not established. We review the genetics of major dyslipidaemias in context of clinical practice.
Recent findings: Genetic testing for familial hypercholesterolaemia is valuable to enhance diagnostic precision, cascade testing, risk prediction and the use of new medications. Hypertriglyceridaemia may be caused by rare recessive monogenic, or by polygenic, gene variants; genetic testing may be useful in the former, for which antisense therapy targeting apoC-III has been approved. Familial high-density lipoprotein deficiency is caused by specific genetic mutations, but there is no effective therapy. Familial combined hyperlipidaemia (FCHL) is caused by polygenic variants for which there is no specific gene testing panel. Familial dysbetalipoproteinaemia is less frequent and commonly caused by APOE ε2ε2 homozygosity; as with FCHL, it is responsive to lifestyle modifications and statins or/and fibrates. Elevated lipoprotein(a) is a quantitative genetic trait whose value in risk prediction over-rides genetic testing; treatment relies on RNA therapeutics.
Summary: Genetic testing is not at present commonly available for managing dyslipidaemias. Rapidly advancing technology may presage wider use, but its worth will require demonstration of cost-effectiveness and a healthcare workforce trained in genomic medicine.
Similar articles
- Demystifying the Management of HypertriglyceridaemiaGF Watts et al. Nat Rev Cardiol 10 (11), 648-61. PMID 24060958. - ReviewHypertriglyceridaemia (typical triglyceride level 1.7-5.0 mmol/l) is caused by interactions between many genetic and nongenetic factors, and is a common risk factor for a …
- Practical Definitions of Severe Versus Familial Hypercholesterolaemia and Hypertriglyceridaemia for Adult Clinical PracticeA Garg et al. Lancet Diabetes Endocrinol 7 (11), 880-886. PMID 31445954. - ReviewDiagnostic scoring systems for familial hypercholesterolaemia and familial chylomicronaemia syndrome often cannot differentiate between adults who have extreme dyslipidae …
- Improving the Cost-Effectiveness Equation of Cascade Testing for Familial HypercholesterolaemiaR Pears et al. Curr Opin Lipidol 26 (3), 162-8. PMID 25887683. - ReviewAlthough all patients with a clinical diagnosis of familial hypercholesterolaemia need to have their LDL-C lowered, cascade testing should be focused on those with the mo …
- The Genetic Architecture of the Familial Hyperlipidaemia Syndromes: Rare Mutations and Common Variants in Multiple GenesPJ Talmud et al. Curr Opin Lipidol 25 (4), 274-81. PMID 24977977.These findings have wider implications for understanding complex disorders, and may very well explain the genetic basis of familial combined hyperlipidaemia, another fami …
- The Role of Genetic Testing in DyslipidaemiaAJ Berberich et al. Pathology 51 (2), 184-192. PMID 30558903. - ReviewDyslipidaemias encompass about two dozen relatively rare monogenic disorders and syndromes for which the genetic basis has largely been defined. In addition, the complex …
No hay comentarios:
Publicar un comentario